Brief: AB Science Granted Authorization To Initiate Study Of AB8939
Oct 18 (Reuters) - AB SCIENCE SA ABS.PA :
* AB SCIENCE GRANTED AUTHORIZATION FROM THE FRENCH HEALTH
AUTHORITY (ANSM) TO INITIATE A STUDY OF AB8939 IN THE TREATMENT
OF ACUTE MYELOID LEUKEMIA (AML)
* SECOND AUTHORIZATION FOR PHASE I/II TRIAL AB18001 PERMITS
PATIENT RECRUITMENT FROM STUDY SITES IN FRANCE AND CANADA
Source text for Eikon: ID:nGNE3k08xy
Further company coverage: ABS.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041